Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | GEN2 + Valganciclovir |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
GEN2 | GEN 2|GEN-2 | GEN2 comprises a non-replicating retroviral vector expressing herpes simplex virus thymidine kinase (HSV-TK) and GM-CSF, which potentially enhances antitumor immune response and induces tumor cell death (Cancer Res (2024) 84 (6_Supplement): 7250, NCI Drug Dictionary). | ||
Valganciclovir | Valcyte |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06391918 | Phase I | GEN2 + Valganciclovir | Phase 1 Study of GEN2 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |